<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01294787</url>
  </required_header>
  <id_info>
    <org_study_id>CQVA149A2305</org_study_id>
    <secondary_id>2010-022721-14</secondary_id>
    <nct_id>NCT01294787</nct_id>
  </id_info>
  <brief_title>Effect of QVA149 on Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <acronym>BRIGHT</acronym>
  <official_title>A Randomized, Blinded, Double Dummy, Multi-center, Placebo Controlled, 3 Period, Crossover Study to Assess the Effect of QVA149 (110/50 µg o.d.) on Exercise Endurance in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD), Using Tiotropium as an Active Control.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study assessed the effect of once-daily indacaterol and glycopyrronium bromide (QVA149)
      on exercise endurance in patients with moderate to severe Chronic Obstructive Pulmonary
      Disease (COPD).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Exercise Tolerance Comparison Between QVA149 and Placebo Groups</measure>
    <time_frame>3 weeks</time_frame>
    <description>The effect of indacaterol and glycopyrronium bromide (QVA149) compared to placebo was measured by exercise endurance time (in seconds) during a sub-maximal constant load cycle ergometry test ((SMETT)which is a cycle exercise test) after three weeks of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dynamic Inspiratory Capacity Comparison Between QVA149 and Placebo Groups</measure>
    <time_frame>3 weeks</time_frame>
    <description>The effect of indacaterol and glycopyrronium bromide (QVA149) compared to placebo was measured using dynamic inspiratory capacity at isotime during sub-maximal constant load cycle ergometry test ((SMETT)a cycle exercise test), after three weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough 24 Hour Post Dose Inspiratory Capacity Comparison Between QVA149 and Placebo Groups</measure>
    <time_frame>3 weeks</time_frame>
    <description>The effect of indacaterol and glycopyrronium bromide (QVA149) compared to placebo was measured using trough 24 hour post dose inspiratory capacity after three weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough 24 Hour Post Dose Forced Expiratory Volume in One Second Comparison Between QVA149 and Placebo Groups</measure>
    <time_frame>3 weeks</time_frame>
    <description>The effect of indacaterol and glycopyrronium bromide (QVA149) compared to placebo was measured using trough 24 hour post dose Forced Expiratory Volume in one second (FEV1) after three weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Function Test Comparison Between QVA149 and Placebo Groups</measure>
    <time_frame>day 1 and day 21</time_frame>
    <description>The effect of indacaterol and glycopyrronium bromide (QVA149) compared to placebo was measured using the pulmonary function test for Slow Vital Capacity (SVC) on day 1 and day 21, at 5 min and 15 min post dose as determined by body plethysmography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Function Test (RV) Comparison Between QVA149 and Placebo Groups</measure>
    <time_frame>day 1 and day 21</time_frame>
    <description>The effect of indacaterol and glycopyrronium bromide (QVA149) compared to placebo was measured using the pulmonary function test for Residual Volume (RV) on day 1 and day 21, at 5 min and 15 min post dose as determined by body plethysmography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Function Test (SGaw) Comparison Between QVA149 and Placebo Groups</measure>
    <time_frame>day 1 and day 21</time_frame>
    <description>The effect of indacaterol and glycopyrronium bromide (QVA149) compared to placebo was measured using the pulmonary function test for Specific Airway Conductance (SGaw) on day 1 and day 21, at 5 min and 15 min post dose as determined by body plethysmography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Function Test (FRC) Comparison Between QVA149 and Placebo Groups</measure>
    <time_frame>day 1 and day 21</time_frame>
    <description>The effect of indacaterol and glycopyrronium bromide (QVA149) compared to placebo was measured using the pulmonary function test for Functional Residual Capacity (FRC) on day 1 and day 21, at 5 min and 15 min post dose as determined by body plethysmography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spirometry After Three Weeks of Treatment on Patients Not Exercising</measure>
    <time_frame>3 weeks</time_frame>
    <description>The effect of indacaterol and glycopyrronium bromide (QVA149) compared to placebo was measured using dynamic inspiratory capacity post-dose pre-exercise after three weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exertional Dyspnea Comparison Between QVA149 and Placebo Groups</measure>
    <time_frame>3 weeks</time_frame>
    <description>The effect of indacaterol and glycopyrronium bromide (QVA149) compared to placebo was measured using exertional dyspnea Borg CR10 Scale® (After 3 weeks of treatment, before, during and after exercise, patients were asked to rate the intensity of their breathing and leg discomfort using the Borg CR10 Scale®). This scale consists of 12-point score that the participants pointed to so as to indicate their level of dyspnea before and during exercise testing (where 0 indicates no breathlessness at all and 12 indicates maximum breathlessness).
A reduction in this score indicates an improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leg Discomfort During Exercise Comparison Between QVA149 and Placebo Groups</measure>
    <time_frame>3 weeks</time_frame>
    <description>The effect of indacaterol and glycopyrronium bromide (QVA149) compared to placebo on leg discomfort was measured using Borg CR10 Scale® during sub-maximal constant load cycle ergometry test after three weeks treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exercise Endurance Comparison Between QVA149 and Tiotropium Groups</measure>
    <time_frame>3 weeks</time_frame>
    <description>Effect of QVA149 110/50 µg o.d. compared with tiotropium 18 µg o.d. in patients with moderate to severe COPD with respect to exercise endurance was measured by a sub-maximal constant load cycle ergometry test ((SMETT)cycle exercise test) after three weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exercise Endurance Time Comparison After a Single Dose of QVA149 Versus Placebo</measure>
    <time_frame>Day 1</time_frame>
    <description>The effect of a single dose of indacaterol and glycopyrronium bromide (QVA149) compared to placebo was measured with respect to exercise endurance time during sub-maximal constant load cycle ergometry test ((SMETT)cycle exercise test).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">85</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>indacaterol and glycopyrronium bromide (QVA149)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>QVA149 delivered once daily via single-dose dry powder inhaler.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, delivered once daily via single-dose dry powder inhaler.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tiotropium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tiotropium delivered once daily via HandiHaler® device.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>indacaterol and glycopyrronium bromide (QVA149)</intervention_name>
    <arm_group_label>indacaterol and glycopyrronium bromide (QVA149)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tiotropium</intervention_name>
    <arm_group_label>tiotropium</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of moderate to severe stable Chronic Obstructive Pulmonary Disease (COPD)
             stage II or stage III according to the Global Initiative for Chronic Obstructive Lung
             Disease (GOLD) Guidelines (2009)

          -  Qualifying spirometry, Forced Expiratory Volume in one second (FEV1) and
             post-bronchodilator FEV1/FVC (Forced Vital capacity)

          -  Smoking history ≥ 10 pack years

        Exclusion Criteria:

          -  Pregnant women or nursing mothers or women of child-bearing potential not using
             adequate contraception

          -  Cardiac abnormality

          -  History of asthma

          -  Contraindications to cardiopulmonary exercise testing

          -  Participation in active phase of pulmonary rehabilitation program

          -  History of cancer within the past 5 years

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Grosshansdorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lubeck</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rudersdorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wiesbaden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barakaldo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Malaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2011</study_first_submitted>
  <study_first_submitted_qc>February 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2011</study_first_posted>
  <results_first_submitted>November 29, 2012</results_first_submitted>
  <results_first_submitted_qc>March 19, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 20, 2013</results_first_posted>
  <last_update_submitted>March 19, 2013</last_update_submitted>
  <last_update_submitted_qc>March 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>QVA149</keyword>
  <keyword>tiotropium</keyword>
  <keyword>exercise</keyword>
  <keyword>exercise tolerance</keyword>
  <keyword>combination bronchodilator</keyword>
  <keyword>moderate to severe COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Glycopyrrolate</mesh_term>
    <mesh_term>Bromides</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study consisted of a maximum 28 day screening period, and three, 3-week treatment periods followed by a study completion evaluation. A washout of 21 days was used to separate the treatment periods.</recruitment_details>
      <pre_assignment_details>A total of 85 patients were randomized and 73 patients completed the study. Since this was a cross-over study a participant may be counted in more than 1 group: 77 participants were treated with QVA149, 83 participants treated with tiotropium and 77 participants treated with placebo. One randomized patient did not receive study drug.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>QVA149 / Placebo / Tiotropium</title>
          <description>Participants received three, 3-week treatment periods followed by a study completion evaluation. A washout of 21 days was used to separate the treatment periods.</description>
        </group>
        <group group_id="P2">
          <title>QVA149 / Tiotropium / Placebo</title>
          <description>Participants received three, 3-week treatment periods followed by a study completion evaluation. A washout of 21 days was used to separate the treatment periods.</description>
        </group>
        <group group_id="P3">
          <title>Placebo / QVA149 / Tiotropium</title>
          <description>Participants received three, 3-week treatment periods followed by a study completion evaluation. A washout of 21 days was used to separate the treatment periods.</description>
        </group>
        <group group_id="P4">
          <title>Placebo / Tiotropium / QVA149</title>
          <description>Participants received three, 3-week treatment periods followed by a study completion evaluation. A washout of 21 days was used to separate the treatment periods.</description>
        </group>
        <group group_id="P5">
          <title>Tiotropium / QAV149 / Placebo</title>
          <description>Participants received three, 3-week treatment periods followed by a study completion evaluation. A washout of 21 days was used to separate the treatment periods.</description>
        </group>
        <group group_id="P6">
          <title>Tiotropium / Placebo / QVA149</title>
          <description>Participants received three, 3-week treatment periods followed by a study completion evaluation. A washout of 21 days was used to separate the treatment periods.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="16"/>
                <participants group_id="P6" count="15">One randomized participant did not receive study drug</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="14"/>
                <participants group_id="P6" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative problem</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="14"/>
                <participants group_id="P6" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="14"/>
                <participants group_id="P6" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No longer needs study drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="14"/>
                <participants group_id="P6" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="13"/>
                <participants group_id="P6" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
          <description>Participants received three, 3-week treatment periods followed by a study completion evaluation. A washout of 21 days was used to separate the treatment periods. One participant was randomized but did not receive study drug.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="84"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>All participants</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.1" spread="8.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Exercise Tolerance Comparison Between QVA149 and Placebo Groups</title>
        <description>The effect of indacaterol and glycopyrronium bromide (QVA149) compared to placebo was measured by exercise endurance time (in seconds) during a sub-maximal constant load cycle ergometry test ((SMETT)which is a cycle exercise test) after three weeks of treatment.</description>
        <time_frame>3 weeks</time_frame>
        <population>Participants from the Full Analysis Set, defined as all randomized participants who received at least one dose of study drug, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>QVA149</title>
            <description>Indacaterol and glycopyrronium bromide (QVA149) delivered once daily via single-dose dry powder inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, delivered once daily via single-dose dry powder inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Exercise Tolerance Comparison Between QVA149 and Placebo Groups</title>
          <description>The effect of indacaterol and glycopyrronium bromide (QVA149) compared to placebo was measured by exercise endurance time (in seconds) during a sub-maximal constant load cycle ergometry test ((SMETT)which is a cycle exercise test) after three weeks of treatment.</description>
          <population>Participants from the Full Analysis Set, defined as all randomized participants who received at least one dose of study drug, with data available for analysis.</population>
          <units>Seconds</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="507.8" spread="19.30"/>
                    <measurement group_id="O2" value="448.3" spread="19.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dynamic Inspiratory Capacity Comparison Between QVA149 and Placebo Groups</title>
        <description>The effect of indacaterol and glycopyrronium bromide (QVA149) compared to placebo was measured using dynamic inspiratory capacity at isotime during sub-maximal constant load cycle ergometry test ((SMETT)a cycle exercise test), after three weeks of treatment.</description>
        <time_frame>3 weeks</time_frame>
        <population>Participants from the Full Analysis Set, defined as all randomized participants who received at least one dose of study drug, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>QVA149</title>
            <description>Indacaterol and glycopyrronium bromide (QVA149) delivered once daily via single-dose dry powder inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>Tiotropium delivered once daily via HandiHaler® device.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, delivered once daily via single-dose dry powder inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Dynamic Inspiratory Capacity Comparison Between QVA149 and Placebo Groups</title>
          <description>The effect of indacaterol and glycopyrronium bromide (QVA149) compared to placebo was measured using dynamic inspiratory capacity at isotime during sub-maximal constant load cycle ergometry test ((SMETT)a cycle exercise test), after three weeks of treatment.</description>
          <population>Participants from the Full Analysis Set, defined as all randomized participants who received at least one dose of study drug, with data available for analysis.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.42" spread="0.034"/>
                    <measurement group_id="O2" value="2.29" spread="0.033"/>
                    <measurement group_id="O3" value="2.11" spread="0.035"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough 24 Hour Post Dose Inspiratory Capacity Comparison Between QVA149 and Placebo Groups</title>
        <description>The effect of indacaterol and glycopyrronium bromide (QVA149) compared to placebo was measured using trough 24 hour post dose inspiratory capacity after three weeks of treatment.</description>
        <time_frame>3 weeks</time_frame>
        <population>Participants from the Full Analysis Set, defined as all randomized participants who received at least one dose of study drug, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>QVA149</title>
            <description>Indacaterol and glycopyrronium bromide (QVA149) delivered once daily via single-dose dry powder inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>Tiotropium delivered once daily via HandiHaler® device.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, delivered once daily via single-dose dry powder inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Trough 24 Hour Post Dose Inspiratory Capacity Comparison Between QVA149 and Placebo Groups</title>
          <description>The effect of indacaterol and glycopyrronium bromide (QVA149) compared to placebo was measured using trough 24 hour post dose inspiratory capacity after three weeks of treatment.</description>
          <population>Participants from the Full Analysis Set, defined as all randomized participants who received at least one dose of study drug, with data available for analysis.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.25" spread="0.035"/>
                    <measurement group_id="O2" value="2.10" spread="0.034"/>
                    <measurement group_id="O3" value="2.06" spread="0.035"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough 24 Hour Post Dose Forced Expiratory Volume in One Second Comparison Between QVA149 and Placebo Groups</title>
        <description>The effect of indacaterol and glycopyrronium bromide (QVA149) compared to placebo was measured using trough 24 hour post dose Forced Expiratory Volume in one second (FEV1) after three weeks of treatment.</description>
        <time_frame>3 weeks</time_frame>
        <population>Participants from the Full Analysis Set, defined as all randomized participants who received at least one dose of study drug, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>QVA149</title>
            <description>Indacaterol and glycopyrronium bromide (QVA149) delivered once daily via single-dose dry powder inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>Tiotropium delivered once daily via HandiHaler® device.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, delivered once daily via single-dose dry powder inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Trough 24 Hour Post Dose Forced Expiratory Volume in One Second Comparison Between QVA149 and Placebo Groups</title>
          <description>The effect of indacaterol and glycopyrronium bromide (QVA149) compared to placebo was measured using trough 24 hour post dose Forced Expiratory Volume in one second (FEV1) after three weeks of treatment.</description>
          <population>Participants from the Full Analysis Set, defined as all randomized participants who received at least one dose of study drug, with data available for analysis.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.53" spread="0.020"/>
                    <measurement group_id="O2" value="1.43" spread="0.020"/>
                    <measurement group_id="O3" value="1.33" spread="0.021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pulmonary Function Test Comparison Between QVA149 and Placebo Groups</title>
        <description>The effect of indacaterol and glycopyrronium bromide (QVA149) compared to placebo was measured using the pulmonary function test for Slow Vital Capacity (SVC) on day 1 and day 21, at 5 min and 15 min post dose as determined by body plethysmography.</description>
        <time_frame>day 1 and day 21</time_frame>
        <population>Participants from the Full Analysis Set, defined as all randomized participants who received at least one dose of study drug, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>QVA149</title>
            <description>Indacaterol and glycopyrronium bromide (QVA149) delivered once daily via single-dose dry powder inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>Tiotropium delivered once daily via HandiHaler® device.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, delivered once daily via single-dose dry powder inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Pulmonary Function Test Comparison Between QVA149 and Placebo Groups</title>
          <description>The effect of indacaterol and glycopyrronium bromide (QVA149) compared to placebo was measured using the pulmonary function test for Slow Vital Capacity (SVC) on day 1 and day 21, at 5 min and 15 min post dose as determined by body plethysmography.</description>
          <population>Participants from the Full Analysis Set, defined as all randomized participants who received at least one dose of study drug, with data available for analysis.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1- 5 min post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.37" spread="0.028"/>
                    <measurement group_id="O2" value="3.22" spread="0.027"/>
                    <measurement group_id="O3" value="3.14" spread="0.028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1- 15 min post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.43" spread="0.026"/>
                    <measurement group_id="O2" value="3.32" spread="0.025"/>
                    <measurement group_id="O3" value="3.16" spread="0.026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21- 5 min post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.37" spread="0.037"/>
                    <measurement group_id="O2" value="3.26" spread="0.036"/>
                    <measurement group_id="O3" value="3.08" spread="0.038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21- 15 min post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.38" spread="0.040"/>
                    <measurement group_id="O2" value="3.29" spread="0.038"/>
                    <measurement group_id="O3" value="3.09" spread="0.039"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pulmonary Function Test (RV) Comparison Between QVA149 and Placebo Groups</title>
        <description>The effect of indacaterol and glycopyrronium bromide (QVA149) compared to placebo was measured using the pulmonary function test for Residual Volume (RV) on day 1 and day 21, at 5 min and 15 min post dose as determined by body plethysmography.</description>
        <time_frame>day 1 and day 21</time_frame>
        <population>Participants from the Full Analysis Set, defined as all randomized participants who received at least one dose of study drug, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>QVA149</title>
            <description>Indacaterol and glycopyrronium bromide (QVA149) delivered once daily via single-dose dry powder inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>Tiotropium delivered once daily via HandiHaler® device.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, delivered once daily via single-dose dry powder inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Pulmonary Function Test (RV) Comparison Between QVA149 and Placebo Groups</title>
          <description>The effect of indacaterol and glycopyrronium bromide (QVA149) compared to placebo was measured using the pulmonary function test for Residual Volume (RV) on day 1 and day 21, at 5 min and 15 min post dose as determined by body plethysmography.</description>
          <population>Participants from the Full Analysis Set, defined as all randomized participants who received at least one dose of study drug, with data available for analysis.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 - 5 min post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.66" spread="0.051"/>
                    <measurement group_id="O2" value="3.89" spread="0.048"/>
                    <measurement group_id="O3" value="3.94" spread="0.050"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 - 15 min post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.63" spread="0.048"/>
                    <measurement group_id="O2" value="3.66" spread="0.046"/>
                    <measurement group_id="O3" value="3.89" spread="0.048"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21- 5 min post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.58" spread="0.063"/>
                    <measurement group_id="O2" value="3.69" spread="0.061"/>
                    <measurement group_id="O3" value="4.03" spread="0.064"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21- 15 min post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.54" spread="0.066"/>
                    <measurement group_id="O2" value="3.59" spread="0.062"/>
                    <measurement group_id="O3" value="3.96" spread="0.065"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pulmonary Function Test (SGaw) Comparison Between QVA149 and Placebo Groups</title>
        <description>The effect of indacaterol and glycopyrronium bromide (QVA149) compared to placebo was measured using the pulmonary function test for Specific Airway Conductance (SGaw) on day 1 and day 21, at 5 min and 15 min post dose as determined by body plethysmography.</description>
        <time_frame>day 1 and day 21</time_frame>
        <population>Participants from the Full Analysis Set, defined as all randomized participants who received at least one dose of study drug, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>QVA149</title>
            <description>Indacaterol and glycopyrronium bromide (QVA149) delivered once daily via single-dose dry powder inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>Tiotropium delivered once daily via HandiHaler® device.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, delivered once daily via single-dose dry powder inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Pulmonary Function Test (SGaw) Comparison Between QVA149 and Placebo Groups</title>
          <description>The effect of indacaterol and glycopyrronium bromide (QVA149) compared to placebo was measured using the pulmonary function test for Specific Airway Conductance (SGaw) on day 1 and day 21, at 5 min and 15 min post dose as determined by body plethysmography.</description>
          <population>Participants from the Full Analysis Set, defined as all randomized participants who received at least one dose of study drug, with data available for analysis.</population>
          <units>Kilo Pascal per second</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1- 5 min post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.71" spread="0.035"/>
                    <measurement group_id="O2" value="0.58" spread="0.033"/>
                    <measurement group_id="O3" value="0.50" spread="0.035"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1- 15 min post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.71" spread="0.064"/>
                    <measurement group_id="O2" value="0.79" spread="0.061"/>
                    <measurement group_id="O3" value="0.50" spread="0.063"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21- 5 min post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.76" spread="0.041"/>
                    <measurement group_id="O2" value="0.64" spread="0.039"/>
                    <measurement group_id="O3" value="0.50" spread="0.041"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21- 15 min post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.79" spread="0.039"/>
                    <measurement group_id="O2" value="0.67" spread="0.038"/>
                    <measurement group_id="O3" value="0.47" spread="0.038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pulmonary Function Test (FRC) Comparison Between QVA149 and Placebo Groups</title>
        <description>The effect of indacaterol and glycopyrronium bromide (QVA149) compared to placebo was measured using the pulmonary function test for Functional Residual Capacity (FRC) on day 1 and day 21, at 5 min and 15 min post dose as determined by body plethysmography.</description>
        <time_frame>day 1 and day 21</time_frame>
        <population>Participants from the Full Analysis Set, defined as all randomized participants who received at least one dose of study drug, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>QVA149</title>
            <description>Indacaterol and glycopyrronium bromide (QVA149) delivered once daily via single-dose dry powder inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>Tiotropium delivered once daily via HandiHaler® device.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, delivered once daily via single-dose dry powder inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Pulmonary Function Test (FRC) Comparison Between QVA149 and Placebo Groups</title>
          <description>The effect of indacaterol and glycopyrronium bromide (QVA149) compared to placebo was measured using the pulmonary function test for Functional Residual Capacity (FRC) on day 1 and day 21, at 5 min and 15 min post dose as determined by body plethysmography.</description>
          <population>Participants from the Full Analysis Set, defined as all randomized participants who received at least one dose of study drug, with data available for analysis.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1- 5 min post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.68" spread="0.057"/>
                    <measurement group_id="O2" value="4.78" spread="0.055"/>
                    <measurement group_id="O3" value="4.98" spread="0.057"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1- 15 min post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.62" spread="0.060"/>
                    <measurement group_id="O2" value="4.63" spread="0.058"/>
                    <measurement group_id="O3" value="4.92" spread="0.059"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21- 5 min post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.58" spread="0.068"/>
                    <measurement group_id="O2" value="4.66" spread="0.066"/>
                    <measurement group_id="O3" value="5.00" spread="0.068"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21- 15 min post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.53" spread="0.067"/>
                    <measurement group_id="O2" value="4.55" spread="0.065"/>
                    <measurement group_id="O3" value="4.91" spread="0.067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Spirometry After Three Weeks of Treatment on Patients Not Exercising</title>
        <description>The effect of indacaterol and glycopyrronium bromide (QVA149) compared to placebo was measured using dynamic inspiratory capacity post-dose pre-exercise after three weeks of treatment.</description>
        <time_frame>3 weeks</time_frame>
        <population>Participants from the Full Analysis Set, defined as all randomized participants who received at least one dose of study drug, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Indacaterol and Glycopyrronium Bromide (QVA149)</title>
            <description>QVA149 delivered once daily via single-dose dry powder inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>Tiotropium delivered once daily via HandiHaler® device.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, delivered once daily via single-dose dry powder inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Spirometry After Three Weeks of Treatment on Patients Not Exercising</title>
          <description>The effect of indacaterol and glycopyrronium bromide (QVA149) compared to placebo was measured using dynamic inspiratory capacity post-dose pre-exercise after three weeks of treatment.</description>
          <population>Participants from the Full Analysis Set, defined as all randomized participants who received at least one dose of study drug, with data available for analysis.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.34" spread="0.032"/>
                    <measurement group_id="O2" value="2.19" spread="0.031"/>
                    <measurement group_id="O3" value="2.01" spread="0.033"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Exertional Dyspnea Comparison Between QVA149 and Placebo Groups</title>
        <description>The effect of indacaterol and glycopyrronium bromide (QVA149) compared to placebo was measured using exertional dyspnea Borg CR10 Scale® (After 3 weeks of treatment, before, during and after exercise, patients were asked to rate the intensity of their breathing and leg discomfort using the Borg CR10 Scale®). This scale consists of 12-point score that the participants pointed to so as to indicate their level of dyspnea before and during exercise testing (where 0 indicates no breathlessness at all and 12 indicates maximum breathlessness).
A reduction in this score indicates an improvement.</description>
        <time_frame>3 weeks</time_frame>
        <population>Participants from the Full Analysis Set, defined as all randomized participants who received at least one dose of study drug, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>QVA149</title>
            <description>Indacaterol and glycopyrronium bromide (QVA149) delivered once daily via single-dose dry powder inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>Tiotropium delivered once daily via HandiHaler® device.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, delivered once daily via single-dose dry powder inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Exertional Dyspnea Comparison Between QVA149 and Placebo Groups</title>
          <description>The effect of indacaterol and glycopyrronium bromide (QVA149) compared to placebo was measured using exertional dyspnea Borg CR10 Scale® (After 3 weeks of treatment, before, during and after exercise, patients were asked to rate the intensity of their breathing and leg discomfort using the Borg CR10 Scale®). This scale consists of 12-point score that the participants pointed to so as to indicate their level of dyspnea before and during exercise testing (where 0 indicates no breathlessness at all and 12 indicates maximum breathlessness).
A reduction in this score indicates an improvement.</description>
          <population>Participants from the Full Analysis Set, defined as all randomized participants who received at least one dose of study drug, with data available for analysis.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.77" spread="0.256"/>
                    <measurement group_id="O2" value="3.59" spread="0.248"/>
                    <measurement group_id="O3" value="3.87" spread="0.259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Leg Discomfort During Exercise Comparison Between QVA149 and Placebo Groups</title>
        <description>The effect of indacaterol and glycopyrronium bromide (QVA149) compared to placebo on leg discomfort was measured using Borg CR10 Scale® during sub-maximal constant load cycle ergometry test after three weeks treatment.</description>
        <time_frame>3 weeks</time_frame>
        <population>Participants from the Full Analysis Set, defined as all randomized participants who received at least one dose of study drug, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>QVA149</title>
            <description>Indacaterol and glycopyrronium bromide (QVA149) delivered once daily via single-dose dry powder inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>Tiotropium delivered once daily via HandiHaler® device.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, delivered once daily via single-dose dry powder inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Leg Discomfort During Exercise Comparison Between QVA149 and Placebo Groups</title>
          <description>The effect of indacaterol and glycopyrronium bromide (QVA149) compared to placebo on leg discomfort was measured using Borg CR10 Scale® during sub-maximal constant load cycle ergometry test after three weeks treatment.</description>
          <population>Participants from the Full Analysis Set, defined as all randomized participants who received at least one dose of study drug, with data available for analysis.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.53" spread="0.243"/>
                    <measurement group_id="O2" value="4.57" spread="0.234"/>
                    <measurement group_id="O3" value="4.43" spread="0.245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Exercise Endurance Comparison Between QVA149 and Tiotropium Groups</title>
        <description>Effect of QVA149 110/50 µg o.d. compared with tiotropium 18 µg o.d. in patients with moderate to severe COPD with respect to exercise endurance was measured by a sub-maximal constant load cycle ergometry test ((SMETT)cycle exercise test) after three weeks of treatment.</description>
        <time_frame>3 weeks</time_frame>
        <population>Participants from the Full Analysis Set, defined as all randomized participants who received at least one dose of study drug, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Indacaterol and Glycopyrronium Bromide (QVA149)</title>
            <description>QVA149 delivered once daily via single-dose dry powder inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>Tiotropium delivered once daily via HandiHaler® device.</description>
          </group>
        </group_list>
        <measure>
          <title>Exercise Endurance Comparison Between QVA149 and Tiotropium Groups</title>
          <description>Effect of QVA149 110/50 µg o.d. compared with tiotropium 18 µg o.d. in patients with moderate to severe COPD with respect to exercise endurance was measured by a sub-maximal constant load cycle ergometry test ((SMETT)cycle exercise test) after three weeks of treatment.</description>
          <population>Participants from the Full Analysis Set, defined as all randomized participants who received at least one dose of study drug, with data available for analysis.</population>
          <units>Seconds</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="507.8" spread="19.30"/>
                    <measurement group_id="O2" value="514" spread="18.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Exercise Endurance Time Comparison After a Single Dose of QVA149 Versus Placebo</title>
        <description>The effect of a single dose of indacaterol and glycopyrronium bromide (QVA149) compared to placebo was measured with respect to exercise endurance time during sub-maximal constant load cycle ergometry test ((SMETT)cycle exercise test).</description>
        <time_frame>Day 1</time_frame>
        <population>Participants from the Full Analysis Set, defined as all randomized participants who received at least one dose of study drug, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>QVA149</title>
            <description>Indacaterol and glycopyrronium bromide (QVA149) delivered once daily via single-dose dry powder inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>Tiotropium delivered once daily via HandiHaler® device.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, delivered once daily via single-dose dry powder inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Exercise Endurance Time Comparison After a Single Dose of QVA149 Versus Placebo</title>
          <description>The effect of a single dose of indacaterol and glycopyrronium bromide (QVA149) compared to placebo was measured with respect to exercise endurance time during sub-maximal constant load cycle ergometry test ((SMETT)cycle exercise test).</description>
          <population>Participants from the Full Analysis Set, defined as all randomized participants who received at least one dose of study drug, with data available for analysis.</population>
          <units>Seconds</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="492.8" spread="17.28"/>
                    <measurement group_id="O2" value="481.0" spread="16.77"/>
                    <measurement group_id="O3" value="468.8" spread="17.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Indacaterol and Glycopyrronium Bromide (QVA149)</title>
          <description>QVA149 delivered once daily via single-dose dry powder inhaler.</description>
        </group>
        <group group_id="E2">
          <title>Tiotropium</title>
          <description>Tiotropium delivered once daily via HandiHaler® device.</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo, delivered once daily via single-dose dry powder inhaler.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>41 61 324 1111</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

